Study aim: Determining the effect of methylene blue with supplements on reducing the symptoms of hospitalization and mortality of patients with COVID virus 19 referred to the lung clinic Design: A randomized, controlled trial, based on outpatients with COVID-19, which has two parallel groups. Settings and conduct: COVID-19 patients with positive PCR or HRCT who refer to the lung clinic and are treated with methylene blue at standard dose / day (1mg /kg) and supplements Participants/Inclusion and exclusion criteria: Inclusion Criteria: Outpatients with COVID-19 virus referred to a Lung Clinic Confirmed by HRCT or PCR; SPO2 without Mask after Ten Minutes between 70-96; Age Over 18 Years Old. Exclusion Criteria: Pregnancy; Severe Liver and Heart Disease; Acute Renal Failure Associated with the Need for Dialysis; Glucose 6-Phosphate Dehydrogenase Deficiency. Intervention groups: COVID-19 outpatients treated with standard medical therapy (supportive therapy) and methylene blue and supplements Main outcome variables: Oxygen Pressure Saturation; Respiratory Rate; Headache; Cough; Fever; Shivery; Respiratory Distress; Chest Pain Wall; Vomiting; Diarrhea; Hospital Stay; Mortality Rate after One Month